Tech Company Financing Transactions
Vicebio Funding Round
On 9/23/2024, Vicebio raised $100 million in Series B funding from TCGX, Avoro Ventures and Goldman Sachs.
Transaction Overview
Company Name
Announced On
9/23/2024
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to accelerate development of multivalent respiratory virus vaccines using proprietary molecular clamp technology.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
2nd Floor 168 Shoreditch High Street
London, E1 6RA
UK
London, E1 6RA
UK
Phone
Undisclosed
Website
Email Address
Overview
We were founded to develop the patented Molecular Clamp technology invented at The University of Queensland, Australia and exclusively licensed to Vicebio by UniQuest, the commercialisation company of UQ. The Molecular Clamp technology stabilises viral glycoproteins in "pre-fusion" conformation, to deliver highly protective and ready-to-use fully liquid vaccines.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Emmanuel Hanon
Chief Medical Officer
Giovanni Cioppa
Chief Scientific Officer
Keith Chappell
Chief Technical Officer
Jean Smal
VP - Bus. Development
Juana Magdalena
VP - Regulatory Affairs
Koen Huygens
VP - Regulatory Affairs
Frank Vandendriessche
Browse more venture capital transactions:
Prev: 9/23/2024: Letta venture capital transaction
Next: 9/23/2024: Jump venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs